We’ve all heard President Trump repeatedly speak about a need to bring drug prices “way down.” And 77% of Americans agree that prescription drug costs are unreasonable.
Trump also has gone on record saying that drug companies are “getting away with murder” – a point 73% of Americans agree with, saying drug companies make too much profit.
On November 13, President Trump officially (via Twitter) nominated Alex Azar for Health and Human Services (HHS) Secretary. However, in career drug company disciple Alex Azar, we have someone even less suited to a Cabinet job than the luxury jet-setting Tom Price.
Azar’s resume includes serving as president of Lilly USA LLC, the largest affiliate of Eli Lilly and Company, for several years, and holding various senior roles within the drug industry’s most powerful trade groups, BIO and PhRMA. During his time at Eli Lilly, their insulin prices rose to $255 (as of 2016) for a vial that cost $21 in 1996. The company pled guilty to a crime, resulting in $1.4 billion in criminal and civil fines.
His appointment would contradict Trump’s pledge to “drain the swamp” and change Washington D.C.’s pay-to-play atmosphere, where a revolving door shifts federal regulators to high-ranking corporate execs, and back into government positions.
This website breaks down why Alex Azar is the wrong choice for Secretary of HHS, and how you can take action to tell the members of Senate to just #SayNoToAzar.